glp 1 new indications How Employers Can Optimize Benefits in the Era of GLP-1s GLP-1 drugs are all approved
Description
As of 2026, retatrutide is in Phase 3 clinical trials
23 These symptoms can be severe in some patients, resulting in a pause of dose escalation, and if intolerable GI symptoms continue, a dose adjustment to the previous lower dose or a switch to an alternative GLP-1 RA should be considered
When evaluating individual components of the composite outcome, both oral corticosteroid use (adjusted IRR: 0.54, 95% CI: 0.410.70) and IBD-related hospitalization (adjusted IRR: 0.73, 95% CI: 0.580.91) were significantly lower amongst GLP-1 RA/DPP-4 inhibitor users
Even when these drugs contain the same active ingredients, they are FDA-approved for different indications
Get in touch with Klinic to get access to the best Independent Practitioners that accept your insurance for comprehensive care, available 24/7/365
